CUE

CUE

USD

Cue Biopharma Inc. Common Stock

$0.639+0.011 (1.752%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$0.628

最高价

$0.660

最低价

$0.620

成交量

0.10M

公司基本面

市值

48.1M

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

0.16M

交易所

NCM

货币

USD

52周价格范围

最低价 $0.45当前价 $0.639最高价 $1.989

相关新闻

GlobeNewswire

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

查看更多
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
GlobeNewswire

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

查看更多
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

查看更多
Cue Biopharma to Host Business Update Call and Webcast
GlobeNewswire

Cue Biopharma Announces Proposed Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

查看更多
Cue Biopharma Announces Proposed Public Offering
GlobeNewswire

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Partnership bolsters Boehringer's autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need.The agreement focuses on further research and development of a novel,

查看更多
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases